Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Claude Le Devehat"'
Autor:
Paul Valensi, Jean-Louis Richard, Claude Le Devehat, Richard A Rosenbloom, T. Khodabandehlou, Cherifo Farez, Carolyn LeFante
Publikováno v:
Journal of Diabetes and its Complications. 19:247-253
Background QR-333, a topical compound that contains quercetin, a flavonoid with aldose reductase inhibitor effects, ascorbyl palmitate, and vitamin D 3 , was formulated to decrease the oxidative stress that contributes to peripheral diabetic neuropat
Autor:
Paul, Valensi, Claude, Le Devehat, Jean-Louis, Richard, Cherifo, Farez, Taraneh, Khodabandehlou, Richard A, Rosenbloom, Carolyn, LeFante
Publikováno v:
Journal of diabetes and its complications. 19(5)
QR-333, a topical compound that contains quercetin, a flavonoid with aldose reductase inhibitor effects, ascorbyl palmitate, and vitamin D(3), was formulated to decrease the oxidative stress that contributes to peripheral diabetic neuropathy and thus
Publikováno v:
Scandinavian journal of clinical and laboratory investigation. Supplementum. 156
In twenty control subjects, twenty diabetic patients without macro-angiopathy and forty diabetic patients with an acute and severe arteriopathy of lower limbs, we studied the red cell filterability (TFE) on total blood, the 2–3 diphosphog-lycerate
Publikováno v:
Scandinavian journal of clinical and laboratory investigation. Supplementum. 156
The diabetic's impairment of the red cell filterability is all the more important if the diabetic subject is suffering from an acute and progressive lower limb arteriopathy. Red cell 2–3 diphosphoglycerate (2–3 DPG) increases when red cell filter
Autor:
A. Lemoine, Bernard Herbeth, Claude Le Devehat, Jacqueline Zittoun, Geneviève Potier de Courey
Publikováno v:
Clinical Chemistry. 33:442-443
Autor:
Daniel Boudart, Roselyne Leloup, Patrick Ozanne, A. Lemoine, Claude Le Devehat, Martine Fournier
Publikováno v:
Scandinavian Journal of Clinical and Laboratory Investigation. 41:259-260
Two diabetic populations were determined, one for those under 30 years of age who had no complications and had been insulin-treated for less than 5 years (I), the other for those over 50 who had complications and insulin treatment for more than 5 yea